Cargando…
A human natural antibody to adenocarcinoma that inhibits tumour cell migration.
We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMA...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063195/ https://www.ncbi.nlm.nih.gov/pubmed/9823972 |
_version_ | 1782137287133364224 |
---|---|
author | Koda, K. Nakajima, N. Saito, N. Yasutomi, J. McKnight, M. E. Glassy, M. C. |
author_facet | Koda, K. Nakajima, N. Saito, N. Yasutomi, J. McKnight, M. E. Glassy, M. C. |
author_sort | Koda, K. |
collection | PubMed |
description | We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMAbs, only one, termed SK1, an IgM, was adenocarcinoma specific in the immunohistochemical study. The antigen recognized by SK1 (Ag-SK1) was a glycoprotein with a molecular weight of 42-46 kDa. The expression of Ag-SK1 on carcinoma cells varied according to the cell growth periods but was independent of cell cycle state as elucidated by two-colour fluorescence-activated cell sorter (FACS) analysis. A dot-blot analysis showed that the concentration of Ag-SK1 per total protein differed considerably among eight colon carcinoma cells examined and that the difference was closely correlated with the invasion capacity of the cells as assessed by a microchemotaxis assay. Furthermore, up to 87% of cell migration was inhibited by SK1 in a dose-dependent manner. These data suggested that Ag-SK1 is metabolized and expressed on highly invasive carcinoma cells. In addition, it appears that, although rare, some patients do mount an anti-cancer antigen response in their draining lymph nodes. A HuMAb such as SK1 may be a good candidate for the treatment of cancer invasion and metastasis. IMAGES: |
format | Text |
id | pubmed-2063195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20631952009-09-10 A human natural antibody to adenocarcinoma that inhibits tumour cell migration. Koda, K. Nakajima, N. Saito, N. Yasutomi, J. McKnight, M. E. Glassy, M. C. Br J Cancer Research Article We characterized a natural human antibody to adenocarcinomas and investigated the biological role of this Ab/Ag complex in cancer expansion. Human monoclonal antibodies (HuMAbs) were generated with hybridoma fusion methods using regional nodal lymphocytes of colon carcinoma patients. Among 1036 HuMAbs, only one, termed SK1, an IgM, was adenocarcinoma specific in the immunohistochemical study. The antigen recognized by SK1 (Ag-SK1) was a glycoprotein with a molecular weight of 42-46 kDa. The expression of Ag-SK1 on carcinoma cells varied according to the cell growth periods but was independent of cell cycle state as elucidated by two-colour fluorescence-activated cell sorter (FACS) analysis. A dot-blot analysis showed that the concentration of Ag-SK1 per total protein differed considerably among eight colon carcinoma cells examined and that the difference was closely correlated with the invasion capacity of the cells as assessed by a microchemotaxis assay. Furthermore, up to 87% of cell migration was inhibited by SK1 in a dose-dependent manner. These data suggested that Ag-SK1 is metabolized and expressed on highly invasive carcinoma cells. In addition, it appears that, although rare, some patients do mount an anti-cancer antigen response in their draining lymph nodes. A HuMAb such as SK1 may be a good candidate for the treatment of cancer invasion and metastasis. IMAGES: Nature Publishing Group|1 1998-11 /pmc/articles/PMC2063195/ /pubmed/9823972 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Koda, K. Nakajima, N. Saito, N. Yasutomi, J. McKnight, M. E. Glassy, M. C. A human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
title | A human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
title_full | A human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
title_fullStr | A human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
title_full_unstemmed | A human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
title_short | A human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
title_sort | human natural antibody to adenocarcinoma that inhibits tumour cell migration. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063195/ https://www.ncbi.nlm.nih.gov/pubmed/9823972 |
work_keys_str_mv | AT kodak ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT nakajiman ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT saiton ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT yasutomij ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT mcknightme ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT glassymc ahumannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT kodak humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT nakajiman humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT saiton humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT yasutomij humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT mcknightme humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration AT glassymc humannaturalantibodytoadenocarcinomathatinhibitstumourcellmigration |